Solid Biosciences is trading 5.06% up now at $10.38, with no clear company-specific catalyst identified.
- No clear September 2, 2026, company-specific announcement was identified to explain the move.
- Recent coverage highlighted Cantor’s August 27 price-target increase and anticipation of SGT-003 Phase 1/2 data in late 2026 or early 2027; that catalyst predates the current session.
- The broader market is mixed, so no definitive macro explanation is established.